Cytochrome P450 and Phase II Drug Metabolism Enzymes (CYP and Phase II Enzymes)

The Cytochrome P450 (CYP) system and Phase II enzymes represent the primary enzymatic pathways responsible for the biotransformation of drugs, environmental toxins, and endogenous molecules such as steroids and fatty acids (StatPearls, 2023). Phase I metabolism, dominated by the CYP superfamily of heme-thiolate proteins, typically involves oxidation, reduction, or hydrolysis to introduce or expose functional groups on a substrate (NIH, 2022). Phase II enzymes, including UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), and glutathione S-transferases (GSTs), perform conjugation reactions that significantly increase the water solubility of metabolites, facilitating their excretion via bile or urine (NCBI, 2021). While these systems generally function to detoxify substances, they can also lead to the metabolic activation of pro-drugs or the formation of reactive intermediates that cause hepatotoxicity or DNA damage (PubMed, 2019). Genetic variations in these enzymes, such as those seen in CYP2D6 or UGT1A1, are major determinants of individual drug response and the risk of adverse drug reactions (FDA, 2020). Understanding the interplay between these metabolic phases is vital for predicting drug-drug interactions and optimizing therapeutic dosing in clinical practice.

Other names

Drug metabolism enzymesXenobiotic metabolism systemPhase I and Phase II metabolismBiotransformation enzymesMixed-function oxidase system

Phase I enzymes (CYPs) catalyze the addition of polar groups through oxidation, reduction, and hydrolysis; Phase II enzymes catalyze the conjugation of substrates with endogenous moieties (glucuronic acid, sulfate, glutathione, or acetate) to increase hydrophilicity for renal or biliary excretion.